Citi Pharma Limited
By PSX Investors Zone · Updated October 16, 2026
Citi Pharma Limited (CPHL) is a Pakistan Stock Exchange-listed pharmaceutical manufacturer established in 2012 and listed in 2021. Its principal activities include manufacturing and selling pharmaceutical products, medical chemicals and botanical products. The company’s performance depends on product demand, manufacturing costs, regulatory requirements, raw-material availability, pricing and competition. In FY2026, CPHL reported standalone sales of approximately Rs. 14.00 billion, profit after tax of Rs. 782.60 million and EPS of Rs. 3.43. Investors should review its financial performance, debt, cash flows, valuation, dividend history and latest official Shariah-screening status before making investment decisions.
Company Overview
Citi Pharma Limited (CPHL) is a pharmaceutical company listed on the Pakistan Stock Exchange. It was incorporated as a private limited company on October 8, 2012, converted into a public unlisted company in October 2020, and listed on the PSX on July 9, 2021.
The company's principal activity is the manufacturing and sale of pharmaceuticals, medical chemicals and botanical products. Its factory is located at Bhai Pheru, District Kasur, Pakistan.
Sources: Official PSX company profile | Citi Pharma official website
Business Model
Citi Pharma operates in the pharmaceutical manufacturing sector. Its business performance may be influenced by:
- Demand for pharmaceutical products and medical chemicals.
- Availability and cost of raw materials.
- Manufacturing capacity, efficiency and quality-control systems.
- Product registration and regulatory requirements.
- Pricing policies and competition in the pharmaceutical market.
- Working-capital requirements, inventory and customer collections.
- Investment in new products, facilities and manufacturing capabilities.
Investors should review the company's annual report to understand its product mix, customer concentration, production capacity and any material expansion plans.
Fundamental Analysis
Annual Financial Performance
The following figures are based on Citi Pharma's published financial highlights and the PSX financial profile. Amounts are in Pakistani rupees and represent standalone figures, unless otherwise stated.
| Financial metric | FY2026 | FY2025 |
|---|---|---|
| Net sales | Rs. 14.005 billion | Rs. 13.154 billion |
| Profit after tax | Rs. 782.60 million | Rs. 892.04 million |
| Earnings per share (EPS) | Rs. 3.43 | Rs. 3.90 |
| Gross profit margin | 17.49% | 15.34% |
| Net profit margin | 5.59% | 6.78% |
| Return on capital employed (ROCE) | 15.00% | 15.00% |
| Current ratio | 1.26 | 1.30 |
| Debt-to-equity ratio | 67% | 70% |
Sources: Citi Pharma financial highlights | PSX CPHL profile
What the Figures Indicate
Sales increased by approximately 6.5% in FY2026 compared with FY2025. However, profit after tax decreased by approximately 12.3%, and EPS fell from Rs. 3.90 to Rs. 3.43.
The gross profit margin improved from 15.34% to 17.49%, while the net profit margin declined from 6.78% to 5.59%. This indicates that stronger gross margins did not translate into higher net profitability.
Investors should investigate operating expenses, financing costs, taxation and cash-flow movements to understand the decline in earnings.
ROA and ROE
Return on Assets (ROA): Verify from the latest annual report. A consistent calculation typically uses net profit divided by average total assets.
Return on Equity (ROE): Verify from the latest annual report. A consistent calculation typically uses profit attributable to ordinary shareholders divided by average shareholders' equity.
These ratios are not included here as confirmed values because they require a consistent calculation basis. Do not substitute ROCE for ROA or ROE.
Quarterly Performance
PSX's standardized financial profile reports the following figures for FY2026:
| Financial metric | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 |
|---|---|---|---|
| Sales | Rs. 3.370 billion | Rs. 4.333 billion | Rs. 3.085 billion |
| Profit after tax | Rs. 203.69 million | Rs. 404.33 million | Rs. 275.42 million |
| EPS | Rs. 0.89 | Rs. 1.77 | Rs. 1.21 |
These figures show variation in quarterly revenue and earnings. Investors should compare each quarter with the same period in the previous year and consult the original interim reports before drawing conclusions.
Source: Official PSX CPHL profile
Share Price, P/E Ratio and 52-Week Range
The PSX profile displayed the following market information on October 7, 2026:
| Market metric | Value |
|---|---|
| Share price | Rs. 65.05 |
| P/E ratio (TTM) | 18.97 |
| 52-week high | Rs. 96.79 |
| 52-week low | Rs. 64.45 |
Important: These are historical market figures, not live prices. Refresh them from the official PSX profile before publishing.
A P/E ratio compares the share price with trailing earnings per share. It should be considered alongside earnings growth, debt, cash flow, industry conditions and business risks. A P/E ratio alone cannot establish whether a stock is undervalued or overvalued.
Source: PSX CPHL profile
Dividend Information
Citi Pharma's FY2026 financial results announcement reported that the Board did not recommend a cash dividend, bonus shares or rights issue for the year.
Investors should check subsequent announcements before relying on this as the company's latest dividend position. Do not assume future dividends or calculate a current dividend yield without checking the latest declared dividend and current share price.
Sources: PSX CPHL announcements | Citi Pharma investor information
Shariah Compliance Status
The PSX-KMI screening notice dated May 29, 2026 listed Citi Pharma Limited (CPHL) as Shariah-compliant, based on financial data as of December 31, 2025.
The notice reported the following screening ratios:
| Screening measure | Reported result |
|---|---|
| Debt ratio | 27.85% |
| Non-compliant investments / total assets | 1.45% |
| Non-compliant income ratio | 0.70% |
| Illiquid assets / total assets | 60.07% |
| Final status in that notice | Compliant |
The screening result applies to the stated review period and may change in later reviews. Verify the latest official PSX-KMI screening notice and any applicable purification guidance before publishing or relying on this status.
Source: Official PSX-KMI screening notice
Key Risks for Investors
- Profitability risk: FY2026 earnings and EPS declined despite higher sales.
- Raw-material costs: Price and availability changes can affect manufacturing margins.
- Regulatory risk: Pharmaceutical manufacturing is subject to product-quality and regulatory requirements.
- Competition: Pricing pressure and competition may affect sales and profitability.
- Working-capital risk: Inventory and customer receivables can affect cash flow.
- Leverage: Review borrowings, finance costs and debt maturity information in the latest annual report.
- Valuation risk: Market multiples may change quickly as earnings and share prices move.
- Shariah-screening risk: Verify the latest official screening result rather than relying on an older status.
What Investors Should Monitor
- Quarterly sales, profit after tax and EPS.
- Gross and net profit margins.
- Raw-material costs and operating expenses.
- Borrowings, finance costs, inventory and operating cash flow.
- Product launches, capacity expansions and material announcements.
- Dividend decisions and entitlement dates.
- Current PSX notices and the latest Shariah-screening status.
Frequently Asked Questions
What does Citi Pharma Limited do?
Citi Pharma manufactures and sells pharmaceutical products, medical chemicals and botanical products.
Was Citi Pharma profitable in FY2026?
Yes. Its standalone financial highlights report profit after tax of approximately Rs. 782.60 million and EPS of Rs. 3.43 for FY2026.
Did Citi Pharma recommend a dividend for FY2026?
No. The FY2026 results announcement reported no cash dividend, bonus shares or rights issue recommended for that year.
Is CPHL Shariah-compliant?
The PSX-KMI screening notice dated May 29, 2026 listed CPHL as compliant based on December 31, 2025 financial data. Check the latest official notice before relying on this status.
Where can I find official financial reports?
Visit the Citi Pharma investor information page or the PSX CPHL profile.
Disclaimer
This profile is for educational and informational purposes only. It is not a recommendation to buy or sell CPHL shares and does not promise profits or investment outcomes. Verify the latest annual report, interim results, market data, dividend announcements, PSX notices and Shariah-screening status before making an investment decision.
This profile is for educational purposes and is not a recommendation to buy or sell any security.